📱 Now on iPhone — live scores, valuations & alerts on the go
1 free score card remaining
Inhibikase Therapeutics, Inc. (IKT)
Healthcare
Inconclusive
weak
$2.5
Updated: 2026-08-31
41
TradeApes Score
Financial Strength
50
Mixed
Operating Trend
55
Mixed
Relative Value
40
Overvalued
Capital Allocation
10
Stressed
Risk Management
35
Weak
Key Findings
+
Strong revenue growth — sales up more than 20% year over year
−
Significant dilution — share count up more than 5% year over year
Industry Related Stocks
Get IKT and 3,000+ stocks in your pocket
Health scores, fair-value estimates, and full company analysis — free on iPhone.
Download iPhone App
TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor.
The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.
Sign up for our Weekly Sector Leaders Newsletter
11 sector-leading stocks delivered to your inbox every Sunday. Free.
No spam. Unsubscribe anytime.